Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 1/2 trial of its Vaxfectin genital herpes vaccine – a therapeutic inoculation that’s melded vaccine and DNA technologies. Here’s how it works: Vical’s approach directs the immune response in two ways: It teaches immune cells to develop weapons against the […]
Many companies are contending to hit the market first in the race for a genital herpes vaccine. The thread that ties them together? Immunotherapy – the wunderdrug for cancer therapy that’s now showing promise for infectious disease. But it hasn’t always been so, said Agenus CEO Garo Armen, whose immunotherapy approach in both cancer and in infectious disease […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cambridge pharmaceutical maker Genocea remains at the head of the herpes vaccine pack, having newly released another set of positive results for its experimental HSV2 vaccine. The company has found that its herpes vaccine is effective even a year after the initial dosage – cutting down the genital lesion and viral shedding rates substantially over a significant time […]
After decades of stagnancy in the herpes therapeutics space, a real neck-and-neck race is emerging among three biotechs in the immunotherapy space: Genocea and Agenus, both based in Massachusetts, San Diego’s Vical are speeding ahead in developing a herpes vaccine. The idea for these companies is to develop a therapeutic vaccine targeted toward individuals who already have […]